Feature | January 16, 2013

First U.S. Patient Treated with Cook Medical’s Zilver PTX Drug-Eluting Peripheral Stent

Ohio hospital is first to use Zilver PTX stent commercially

January 16, 2013 — Just weeks after the Food and Drug Administration (FDA) approved Cook Medical’s Zilver PTX drug-eluting peripheral stent, Riverside Methodist Hospital in Columbus, Ohio, has treated the first patient with the device as part of Cook’s U.S. commercial launch.

“It was a great honor for my institution to be first to implant Cook Medical’s Zilver PTX as part of the stent’s commercial roll-out,” said Gary Ansel, M.D., director for the Center for Critical Limb Care at Riverside Methodist Hospital. “This technology is so advanced and offers such prolonged patient benefit, I believe it will very quickly challenge older PAD treatments such as balloon angioplasty and bare metal stenting in the U.S. as the standard of PAD care.”

Zilver PTX, approved for use in the above-the-knee femoropopliteal artery, is the only drug-eluting stent approved for use in a peripheral artery in the U.S. The device reduces by more than 50 percent the need for follow-up procedures to reopen the artery. These follow-up procedures can be expensive, which places extra burdens on patients, physicians and facilities.

This combination therapy device combines the mechanical support of stenting with the drug paclitaxel, which limits cell growth that can reclog the artery. The combination has been shown to maintain arterial blood flow to the superficial femoral artery (SFA) in seven out of 10 patients through 24 months after implantation.

The disease Zilver PTX targets, peripheral arterial disease (PAD), is one of the fastest-growing and most pervasive diseases of our time, affecting an estimated 8-12 million Americans each year. PAD is a disease in which plaque builds up in the arteries, which carry blood to the head, organs and limbs. While PAD typically affects arteries in the legs, it can also affect blood flow to the head, arms, kidneys and stomach. People aged 50 and over who have a history of diabetes, smoking and high blood pressure are at higher risk for PAD.

Other treatment modalities for PAD include medical management, lifestyle changes such as exercise, balloon angioplasty, bare metal stenting and surgical bypass of the blocked artery.

For more information: www.cookmedical.com

Related Content

 PLATINUM DIVERSITY, stents in minorities and women
News | Cath Lab| November 09, 2016
November 9, 2016 — A dedicated stent study conducted exclusively in women and minority patients evaluated clinical ou
Sponsored Content | Videos | Stents Bioresorbable| November 09, 2016
Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirb
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Sponsored Content | Videos | Cath Lab| November 08, 2016
David Kandzari, M.D., director of interventional cardiology and chief scientific officer, Piedmont Heart Institute, A
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Bionics trial, Medinol, BioNIR stent, elastic polymer

Imaging of stent struts after expansion, showing the elastic polymer used on Medinol’s BioNIR stent does not crack or flake off, possibly leading to better patient outcomes. 

News | Stents| November 07, 2016
November 7, 2016 – The large multinational randomized BIONICS study found that a novel elastic polymer coated ridafor
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Drug-Filled Stent, DFS, RevElution trial, first clinical data, TCT 2016, Stephen Worthley
News | Stents Drug Eluting| November 01, 2016
November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel...
News | Stents Drug Eluting| October 31, 2016
Micell Technologies Inc. announced that it presented five-year clinical safety and efficacy results from the DESSOLVE I...
Overlay Init